TIA
CTMX icon

Traphagen Investment Advisors’s CytomX Therapeutics CTMX Stock Holding History

Traphagen Investment Advisors’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-30,500
Closed -$19.4K – 190
2025
Q1 		$19.4K Hold
30,500
– – ﹤0.01% 181
2024
Q4 		$31.4K Buy
+30,500
New +$32.8K ﹤0.01% 176

Other funds holding CTMX

VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Traphagen Investment Advisors's CTMX Position: Q2 2025 in Review

Traphagen Investment Advisors sold out of CytomX Therapeutics (CTMX) in Q2 2025, closing a stake of 30,500 shares — an estimated $19.4K sold.

Traphagen Investment Advisors first reported a position in CTMX in Q4 2024 and held it in 2 quarters. The position peaked at $31.4K in Q4 2024. 83 funds tracked by Wall St. Rank hold CTMX as of Q2 2025.

  • Traphagen Investment Advisors reported no remaining CytomX Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Traphagen Investment Advisors sold 30,500 CytomX Therapeutics shares in Q2 2025, an estimated $19.4K.
  • Traphagen Investment Advisors first reported a position in CytomX Therapeutics in Q4 2024 and held it in 2 quarters.
  • Traphagen Investment Advisors's CytomX Therapeutics position peaked at $31.4K in Q4 2024.
  • 83 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q2 2025.

Based on Traphagen Investment Advisors's 13F filing for Q2 2025, filed 23 Jul 2025.